© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
October 04, 2022
The SpyGlass IOL platform showcased a 45% drop in mean intraocular pressure at 3 months in first-in-human glaucoma trial.
Safety data of the bioerodible sustained delivery intravitreal anti-VEGF treatment indicate no ocular or systemic serious adverse events with mild adverse events.
A discussion into safety data from the Phase 3 DERBY and OAKS trials on pegcetacoplan with Dr. Boyer at AAO 2022.
October 03, 2022
New data from AAO 2022 show how technology may refine a currently inefficient enrollment practice for retina disease assessment.
A real-world comparison of the anti-VEGF agents suggests certain doses are associated with more likelihood of retreatment.
Faricimab treatment for both DME and nAMD was able to reliably get to 16 week dosing in 60% of eyes from YOSEMITE and RHINE and TENAYA and LUCERNE.
Findings from the INSIGHT study suggest MYL-1701P may provide a new anti-VEGF biosimilar option to patients with the common form of vision loss.
October 02, 2022
The 48-week results suggest robust CST reduction and visual gains with faricimab up to every 16 week dosing, comparable with aflibercept ever 8-weeks.
The data show 80% of patients were rescue-free up to 6 months with a single OTX-TKI implant injection.
A significant rate of reduction of geographic atrophy growth with pegcetacoplan was observed in both DERBY and OAKS over a 24-month period.
Paul Feuerstadt, MD: The Future of RBX2660
Fighting for Sight: Geographic Atrophy Drug Development Meets Its Future
Aflibercept Outperforms Bevacizumab at Weaning nAMD Patients Off Treatment